What's Happening?
Mammotome, a company under Danaher Corporation, has received FDA clearance for its Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy System and HydroMARK Plus MR Biopsy Site Markers. This system is the first of its kind designed to be used in-room
with MRI scanners, enhancing clinician coordination and patient focus during procedures. The system allows for larger tissue samples and features a touchscreen interface for easy adjustments. The HydroMARK Plus marker is designed for precise deployment and long-term visibility, supporting pre-surgical localization.
Why It's Important?
The FDA clearance of Mammotome's new system represents a significant advancement in breast cancer diagnostics and treatment. By allowing procedures to be conducted directly in the MRI room, the system improves efficiency and precision, potentially leading to better patient outcomes. This innovation could streamline the workflow for clinicians and reduce the time patients spend undergoing biopsies, thus enhancing the overall healthcare experience.
What's Next?
Mammotome plans to introduce the system to U.S. clinicians at the 2026 Society of Breast Imaging Symposium, with availability expected in the summer. The company also intends to expand the rollout to additional countries later in the year. This strategic introduction aims to establish the system as a standard in MR-guided breast biopsies, potentially influencing future developments in medical imaging and diagnostics.
